SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma

British Journal of Dermatology

Volumn 150, Issue 2, 2004, Pages 252-258

  Hartmann, T B ^a   Thiel, D ^a   Dummer, R ^b   Schadendorf, D ^a   Eichmuller S ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antibodies; Cutaneous T cell lymphoma; Humoral immune response; SEREX; Tumour immunology

Indexed keywords

ALDEHYDE REDUCTASE; COMPLEMENTARY DNA; ELONGATION FACTOR 1ALPHA; INOSITOL 1,4,5 TRISPHOSPHATE 5 PHOSPHATASE; MESSENGER RNA; RNA; TUMOR ANTIGEN; VIMENTIN;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; CELL LINE; CONTROLLED STUDY; CROSS REACTION; CUTANEOUS T CELL LYMPHOMA; DISEASE ASSOCIATION; DNA LIBRARY; GENE CONSTRUCT; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR CLONING; MOLECULAR RECOGNITION; MYCOSIS FUNGOIDES; NUCLEOTIDE SEQUENCE; PATIENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SEROLOGICAL IDENTIFICATION OF ANTIGENS BY RECOMBINANT EXPRESSION CLONING; SEROLOGY; SERUM; SEZARY SYNDROME; TISSUE;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; GENE LIBRARY; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE ANALYSIS; SKIN NEOPLASMS;

EID: 1542611539     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.05651.x     Document Type: Article

References (42)

1. Burg G, Kempf W, Häffner A et al. Cutaneous lymphomas. Curr Probl Dermatol 1997; 9: 137-204.
2. Willemze R, Kerl H, Sterry W et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90; 354-71.
3. Weinstock MA, Horm JW. Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. JAMA 1988; 260: 42-6.
4. Jahn S, Asadullah K, Walden P et al. Cutaneous malignant lymphomas. Immunol Today 1998; 19: 100-3.
5. Dummer R. [Cutaneous lymphomas. Quality Assurance Committee of the German Society of Dermatology and the Professional Organization of German Dermatologists e. V.]. Hautarzt 1998; 48 (Suppl. 1): S49-55.
6. Dummer R, Häffner A, Hess M et al. A rational approach to the therapy of cutaneous T-cell lymphomas. Onkologie 1996; 19: 226-30.
7. Stadler R, Otte HG, Luger T et al. Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 3578-81.
8. Disis ML, Calenoff E, McLaughlin G et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994; 54: 16-20.
9. Jäger E, Chen YT, Drijfhout JW et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187: 265-70.
10. Vermeer MH, Doorn R, Dukers D et al. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol 2001; 19: 4322-9.
11. Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med 2001; 250: 462-75.
12. Overwijk WW, Restifo NP. Autoimmunity and the immunotherapy of cancer: targeting the 'self' to destroy the 'other'. Crit Rev Immunol 2000; 20: 433-50.
13. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol 2002; 2: 512-9.
14. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
15. Moingeon P. Cancer vaccines. Vaccine 2001; 19: 1305-26.
16. Türeci Ö, Sahin U, Pfreundschuh M. Serological analysis of human tumour antigens: molecular definition and implications. Mol Med Today 1997; 3: 342-9.
17. Old LJ. Cancer/testis (CT) antigens - a new link between gametogenesis and cancer. Cancer Immunity 2001; 1: 1.
18. Eichmüller S, Usener D, Dummer R et al. Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci USA 2001; 98: 629-34.
19. Kaltoft K, Bisballe S, Dyrberg T et al. Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides. In Vitro Cell Dev Biol 1992; 28A: 161-7.
20. Kaltoft K, Bisballe S, Rasmussen HF et al. C-type particles are inducible in Se-Ax, a continuous T-cell line from a patient with Sézary's syndrome. Arch Dermatol Res 1988; 280: 264-7.
21. Nagase T, Ishikawa K, Miyajima N et al. Prediction of the coding sequences of unidentified human genes. IX. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro. DNA Res 1998; 5: 31-9.
22. De Smedt F, Verjans B, Mailleux P et al. Cloning and expression of human brain type I inositol 1,4,5-trisphosphate 5-phosphatase. High levels of mRNA in cerebellar Purkinje cells. FEBS Lett 1994; 347: 69-72.
23. Herrmann H, Aebi U. Structure, assembly, and dynamics of intermediate filaments. Subcell Biochem 1998; 31: 319-62.
24. Nishimura C, Matsuura Y, Kokai Y et al. Cloning and expression of human aldose reductase. J Biol Chem 1990; 265: 9788-92.
25. Uetsuki T, Naito A, Nagata S et al. Isolation and characterization of the human chromosomal gene for polypeptide chain elongation factor-1 alpha. J Biol Chem 1989; 264: 5791-8.
26. Eichmüller S. Towards defining specific antigens for cutaneous lymphomas. Onkologie 2002; 25: 448-54.
27. Eichmüller S, Usener D, Thiel D et al. Tumour-specific antigens in cutaneous T-cell lymphoma: expression and sero-reactivity. Int J Cancer 2003; 104: 482-7.
28. Dummer R, Kohl O, Gillessen J et al. Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Reduced proliferation and preferential secretion of a T helper-2-like cytokine pattern on stimulation. Arch Dermatol 1993; 129: 433-6.
29. Mitchell CA, Gurung R, Kong AM et al. Inositol polyphosphate 5-phosphatases: lipid phosphatases with flair. IUBMB Life 2002; 53: 25-36.
30. Speed CJ, Little PJ, Hayman JA et al. Underexpression of the 43 kDa inositol polyphosphate 5-phosphatase is associated with cellular transformation. EMBO J 1996; 15: 4852-61.
31. Strehlow I, Lohmann Matthes ML, Decker T. The interferon-inducible GBP1 gene: structure and mapping to human chromosome 1. Gene 1994; 144: 295-9.
32. Herrmann H, Fouquet B, Franke WW. Expression of intermediate filament proteins during development of Xenopus. Development 1989; 105: 279-98.
33. Lang S, Hyde C, Reid I et al. Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 2002; 52: 253-63.
34. Papadopoulos N, Kotini A, Cheva A et al. Immunohistochemical expression of vimentin and secretory component antigens in endometrial hyperplasia and neoplasia. Eur J Gynaecol Oncol 2002; 23: 411-4.
35. Scuric Z, Stain S, Anderson W et al. New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. Hepatology 1998; 27: 943-50.
36. Tatsuka M, Mitsui H, Wada M et al. Elongation factor-1 alpha gene determines susceptibility to transformation. Nature 1992; 359: 333-6.
37. Zhang W, Chen T, Wan T et al. Cloning of DPK, a novel dendritic cell-derived protein kinase activating the ERK1/ERK2 and JNK/SAPK pathways. Biochem Biophys Res Commun 2000; 274: 872-9.
38. Tassi E, Biesova Z, Di Fiore PP et al. Human JIK, a novel member of the STE20 kinase family that inhibits JNK and is negatively regulated by epidermal growth factor. J Biol Chem 1999; 274: 33287-95.
39. Sonenberg N. Translation factors as effectors of cell growth and tumorigenesis. Curr Opin Cell Biol 1993; 5: 955-60.
40. Huang S, Preuss KD, Xie X et al. Analysis of the antibody repertoire of lymphoma patients. Cancer Immunol Immunother 2002; 51: 655-62.
41. Krackhardt AM, Witzens M, Harig S et al. Identification of tumour-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 2002; 100: 2123-31.
42. Haeseleer F, Palczewski K. Short-chain dehydrogenases/reductases in retina. Methods Enzymol 2000; 316: 372-83.